VectivBio Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VectivBio stock.
View analyst ratings for VectivBio or view top-rated stocks.

Wall Street analysts have given VectivBio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VectivBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

4 Wall Street analysts have issued 1-year price targets for VectivBio's stock. Their forecasts range from $19.00 to $28.00. On average, they anticipate VectivBio's stock price to reach $23.67 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for VectivBio or view top-rated stocks among Wall Street analysts.

Some companies that are related to VectivBio include Seer (SEER), Immunocore (IMCR), ImmunityBio (IBRX), BioAtla (BCAB), Edgewise Therapeutics (EWTX), Concordia International (CXR), Cullinan Oncology (CGEM), Nurix Therapeutics (NRIX), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Kinnate Biopharma (KNTE), Connect Biopharma (CNTB), Silverback Therapeutics (SBTX), Stem (STEM) and iTeos Therapeutics (ITOS).
View all of VECT's competitors.

(VECT) raised $128 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

VectivBio trades on the NASDAQ under the ticker symbol "VECT."

VectivBio's quiet period expires on Wednesday, May 19th. VectivBio had issued 7,500,000 shares in its IPO on April 9th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Shares of VECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VECT stock can currently be purchased for approximately $13.77.

VectivBio has a market capitalization of $468.39 million.

The official website for VectivBio is vectivbio.com.

The company can be reached via phone at 41 61 551 30 3.